Jeffrey Curtis, MD, MS, MPH: The Future of Rheumatological Care

Video

Care of rheumatic patients must factor in cradiovascular risk and conditions.

In our previous segment, Jeffrey Curtis, MD, MS, MPH, of the University of Alabama at Birmingham, discussed how rheumatologists must be more attuned to patient risk for cardiovascular (CV) diseases.

CV risk can increase as a result of the rheumatic condition or certain therapies that may have an adverse effect on lipid profiles.

In this final part of our interview, Curtis elaborated a bit further on this shortcoming in rheumatological care and a potential direction for the specialty.

“Although rheumatologists are certain specialists, I think many of us feel rather compelled to get back a bit more to our internal medicine roots,” he said.

This would mean engaging more in CV risk management, such as prescribing appropriate therapies and more actively monitoring aspects of CV health.

Curtis attributed this limitation in care to knowledge and willingness gaps. He believed this assuming of greater responsibility would meet a pushback in the field. After all, rheumatologists are already spread thin with time pressures for treatment.

“It doesn’t have to be that rheumatologists are always the prescribers,” said Curtis. “I think in many offices it’s just not realistic. But we can think through how we can better comanage and how we can communicate more effectively.”

He concluded with a hope that rheumatologists can take on greater responsibility and opportunities to optimize patient outcomes.

Related Videos
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Charles R. Marmar, MD: Blood Biomarkers for PTSD
John Kane, MD: Shifts in Antipsychotics for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.